- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
Sex workers experienced stock-outs of antiretroviral drugs for HIV in more than half of the countries that responded to the consultation, in all types of health care settings. Sex workers experience forced treatment interruptions and involuntary medication changes due to stock-outs, and are forced to travel long distances to access commodities and treatments due to stock-outs in their local areas. This ultimately leads to a lack of trust in health services and systems.
Antiretroviral treatment (ART) optimization is a key pillar in the AIDS Free agenda to reach the goal of ensuring 95% of all infants and children have access to lifesaving treatment.
This policy brief outlines key considerations to facilitate effective transition to more clinically appropriate regimens as optimal ARV medicines and dosage forms become available.
Keywords: HIV, ARV, paediatric, treatment, children
Strong global commitment to end AIDS has driven huge progress. In 2017, around 75% of people living with HIV globally knew their HIV status and 59% of all people living with HIV were accessing treatment.
However, new HIV infections are not declining fast enough and too many people are still dying from AIDS-related illnesses despite the availability of high-quality and effective treatment. And with 36.9 million men, women and children living with HIV around the world, there are more people than ever before living with HIV. A quarter don’t even know that they have the virus.
There is a belief that innovation of new antibiotics will out-pace the development and spread of resistant bacteria. However, without rapidly addressing the way antibiotics are currently over- and mis-used, there is no chance of winning this race. Novel antibiotics will continue to play an important role, but they will not be enough. Antibiotics must be seen as a non-renewable resource. And just like in climate change, if this natural resource is exhausted, there will be nothing left for future generations. Managing antibiotic resistance relies on limiting use of antibiotics, discovery of new antibiotics or alternative ways to treat infectious diseases, but also on preventing infections and limiting spread of resistance. There are no quick fixes – antibiotic resistance is a systems failure and thus all sectors need to contribute to a change and jointly securing that antibiotics remain effective.
This report focuses on the Sustainable Development Goals related to poverty, economic growth, inequality, health, food production and the environment.
Every child and adolescent living with HIV should have access to antiretroviral therapy (ART). The AIDS Free component of the framework has the specific goal of ensuring 95% of all children and adolescents living with HIV have access to lifelong ART by the end of 2018. These efforts will need to be sustained until 2020, when it is estimated that treating 95% of all children and adolescents living with HIV will require providing ART to 1.4 million children (aged 0-14). and 1 million adolescents (aged 15-19).
The decision to take an HIV self-test is yours and yours alone. No one else should force you to take an HIV test, either an HIV self-test or any other type of HIV test.
This report updates the first edition, published in 2016, and reviews the progress countries have made in expanding access to life-saving DAAs. The report reviews the main challenges countries face and describes recent developments in relation to five key factors that determine access to DAA medicines: affordability, quality assurance, regulatory approval, government commitment and financing. It highlights key areas for action by ministries of health and other government decision-makers, pharmaceutical manufacturers and technical partners.
Nearly a quarter of the world’s new HCV infections occur among people who inject drugs (PWID): lack of access to sterile needles, syringes and other injection equipment renders them highly vulnerable to HCV. Legal and structural barriers also greatly increase HCV risk among PWID. Worldwide, more than 50% of the 15.6 million PWID are HCV antibody positive. Without urgent, strategic and measurable action that includes PWID, HCV will continue to inflict a staggering, and increasing, burden of preventable illness and death among families, communities and countries.
The consultation was convened in Malaysia (Putrajaya, 27 to 28 February 2018) by the Malaysian Ministry of Health and WHO to discuss potential approaches for validation of mother-to-child transmission of hepatitis B inviting national and international experts.
Update on antiretroviral regimens for treating and preventing HIV infection: Since 2016, WHO has recommended tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) (or emtricitabine, FTC) + efavirenz (EFV) 600 mg as the preferred first- line antiretroviral therapy (ART) regimen for adults and adolescents. WHO recommended dolutegravir (DTG) as an alternative option to EFV for first-line ART because of the uncertainty regarding the safety and efficacy of DTG during pregnancy and among people living with HIV receiving rifampicin-based tuberculosis (TB) treatment.
Update on early infant diagnosis of HIV: In 2016, WHO recommended that HIV virological testing be used to diagnose HIV infection among infants and children younger than 18 months and that ART be started without delay while a second specimen is collected to confirm the initial positive virological test result.
Keywords: HIV, ART, diagnosis, treatment